Go back

Cardionovum at LINC 2016

Dr. Jean Paul de Vries (PI) presented the patient study results of the multi-center randomized RAPID trial. Legflow was used for pre-dilatation, followed by SUPERA peripheral stent implantation versus POBA , followed by SUPERA stenting. The LEGFOW patient group demonstrates significantly superior patient results after treating extraordinarily complex TASC – C lesions of Real Life patients. Lesion length > 15cm, occlusion rate > 75%, followed by SUPERA peripheral stenting. The study aim showed the power of Legflow to significantly optimize peripheral stenting results.

Detailed information available at Cardionovum GmbH.

Jean Paul de Vries, MD
Jean Paul de Vries, MD